Bramer S - Search Results

1

Effect of Oral Valproic Acid vs Placebo for Vision Loss in Patients With Autosomal Dominant Retinitis Pigmentosa: A Randomized Phase 2 Multicenter Placebo-Controlled Clinical Trial.

Birch DG, Bernstein PS, Iannacone A, Pennesi ME, Lam BL, Heckenlively J, Csaky K, Hartnett ME, Winthrop KL, Jayasundera T, Hughbanks-Wheaton DK, Warner J, Yang P, Fish GE, Teske MP, Sklaver NL, Erker L, Chegarnov E, Smith T, Wahle A, VanVeldhuisen PC, McCormack J, Lindblad R, Bramer S, Rose S, Zilliox P, Francis PJ, Weleber RG. Birch DG, et al. Among authors: bramer s. JAMA Ophthalmol. 2018 Aug 1;136(8):849-856. doi: 10.1001/jamaophthalmol.2018.1171. JAMA Ophthalmol. 2018. PMID: 29879277 Free PMC article. Clinical Trial.

2

Effect of increasing gastric pH with famotidine on the absorption and oral pharmacokinetics of the inotropic agent vesnarinone.

Koneru B, Cowart DT, Noorisa M, Kisicki J, Bramer SL. Koneru B, et al. Among authors: bramer sl. J Clin Pharmacol. 1998 May;38(5):429-32. doi: 10.1002/j.1552-4604.1998.tb04448.x. J Clin Pharmacol. 1998. PMID: 9602955 Clinical Trial.

3

Pharmacokinetics of multiple-dose oral cilostazol in middle-age and elderly men and women.

Suri A, Forbes WP, Bramer SL. Suri A, et al. Among authors: bramer sl. J Clin Pharmacol. 1998 Feb;38(2):144-50. doi: 10.1002/j.1552-4604.1998.tb04403.x. J Clin Pharmacol. 1998. PMID: 9549645 Clinical Trial.

4

Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers.

Mallikaarjun S, Salazar DE, Bramer SL. Mallikaarjun S, et al. Among authors: bramer sl. J Clin Pharmacol. 2004 Feb;44(2):179-87. doi: 10.1177/0091270003261901. J Clin Pharmacol. 2004. PMID: 14747427 Clinical Trial.

5

Effect of disulfiram-mediated CYP2E1 inhibition on the disposition of vesnarinone.

Frye RF, Tammara B, Cowart TD, Bramer SL. Frye RF, et al. Among authors: bramer sl. J Clin Pharmacol. 1999 Nov;39(11):1177-83. J Clin Pharmacol. 1999. PMID: 10579149

6

The effects of concomitant administration of theophylline and toborinone on the pharmacokinetics of both compounds in poor and extensive metabolizers via CYP2D6.

Tammara B, Trang JM, Miyamoto G, Kitani M, Brisson J, Bramer SL. Tammara B, et al. J Clin Pharmacol. 2002 May;42(5):492-500. doi: 10.1177/00912700222011544. J Clin Pharmacol. 2002. PMID: 12017343 Clinical Trial.

7

Effect of cilostazol on the pharmacokinetics and pharmacodynamics of warfarin.

Mallikaarjun S, Bramer SL. Mallikaarjun S, et al. Among authors: bramer sl. Clin Pharmacokinet. 1999;37 Suppl 2:79-86. doi: 10.2165/00003088-199937002-00009. Clin Pharmacokinet. 1999. PMID: 10702890 Clinical Trial.

8

Effect of CYP3A inhibition on vesnarinone metabolism in humans.

Wandel C, Lang CC, Cowart DC, Girard AF, Bramer S, Flockhart DA, Wood AJ. Wandel C, et al. Among authors: bramer s. Clin Pharmacol Ther. 1998 May;63(5):506-11. doi: 10.1016/S0009-9236(98)90101-1. Clin Pharmacol Ther. 1998. PMID: 9630823 Clinical Trial.

9

Effect of renal impairment on the pharmacokinetics of cilostazol and its metabolites.

Mallikaarjun S, Forbes WP, Bramer SL. Mallikaarjun S, et al. Among authors: bramer sl. Clin Pharmacokinet. 1999;37 Suppl 2:33-40. doi: 10.2165/00003088-199937002-00004. Clin Pharmacokinet. 1999. PMID: 10702885 Clinical Trial.

10

The pharmacokinetics of toborinone in subjects with congestive heart failure and concomitant renal impairment and/or concomitant hepatic impairment.

Tammara B, Trang JM, Kitani M, Miyamoto G, Bramer SL. Tammara B, et al. J Clin Pharmacol. 2002 Dec;42(12):1318-25. doi: 10.1177/0091270002042012011. J Clin Pharmacol. 2002. PMID: 12463726 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

103 results

Search Page